annual elrig drug discovery event. our organising committee and session chairs have been working...

www.elrig.org

Welcome to Drug Discovery 2019

As Scientific Program chairs it is our great pleasure to welcome you back to Liverpool for the 13th Annual ELRIG Drug Discovery event. Our organising committee and session chairs have been working hard since late 2018 and thanks to them we have again been able to assemble a world-class line up of scientific speakers. This year we have 8 thematic tracks over 2 days with over 50 invited speakers, over 100 posters and as always a sold out and vibrant exhibition hall.

We encourage you to get to as much of the science as you possibly can and to take full advantage of the exhibitor’s expertise and knowledge to improve your own discovery sciences. The vendor presence at ELRIG ensures that these conferences are of minimal cost to attendees, so please show your appreciation by visiting the booths and asking as many probing and difficult questions of their technology as possible. With these questions they are better equipped to supply us with the tools of the future to make the next set of discoveries.

We are sure there will be something for everyone at this year’s Drug Discovery. We have tried to reflect hot topics and trends in the Drug Discovery field in this year’s tracks and we invite our speakers to take a look back at the future. We aim to ponder on both how we have arrived at this exciting era of drug discovery and to look ahead to what the future may hold. We are also delighted to welcome sessions hosted by the British Pharmacological Society and Cancer Research UK, focusing on ion channels and oncology drug discovery respectively.

We would again like to thank Rhona Bennett, Clare Cockerham, Sanj Kumar and Tara Shanks in the ELRIG office for their fantastic contribution in shepherding ourselves and the Program Chairs through the organising process. Without their help, together with the all the other volunteers, this meeting would not be possible.

Finally, without you, the meeting delegate, we have nothing too. We thank you in advance for your participation and look forward to connecting with you over the next couple of days. As always, we welcome your feedback on how we can further improve the agenda to ensure the growth and success of ELRIG Drug Discovery for the future. Have fun in Liverpool and enjoy the opportunity to discuss emerging Science within a vibrant and collegiate environment!

Katy Kettleborough(LifeArc)

Tim Hammonds (Cancer Research UK)

Chun-wa Chung(GlaxoSmithKline)

A Message from the Chair of ELRIG, Steve Rees On behalf of ELRIG I would like to welcome you to the 13th Drug Discovery meeting and our return to Liverpool. During 2019 ELRIG has held four outstanding scientific events attracting over 1300 delegates. With the 1400 scientists expected to attend Drug Discovery this will be a record year for ELRIG in terms of meeting delegates and vendor exhibitions. Alongside this our networking events programme is now established in major science centres across the UK, and the Early Career Professional Work group has run a series of events to engage with, and support, junior scientists as they embark on their careers.

We have an exciting scientific program in place for 2020. Following the success of our first meeting on CRISPR in Drug Discovery we will be revisiting this topic in March in Cambridge. For the first time our Research and Innovation meeting will be held in Oxford in April, we will be returning to Gothenburg for a Cell Therapy meeting in June and Stevenage for our Flow Cytometry and Imaging meeting in the autumn. Alongside this we look forward to returning to the ExCeL in London for Drug Discovery 2020 in October. The success of ELRIG is dependent upon the many volunteers who give their time freely to create our meetings and other events. Volunteers are supported by an outstanding ELRIG office team; Sanj Kumar, Tara Shanks, Rhona Bennett and Clare Cockerham. I would like to thank everyone involved in ELRIG for the work that they do for this organisation. Looking ahead to the next two days we have an outstanding scientific program to look forward too, together with our largest ever vendor exhibition. I would like to thank the science committee, session chairs, speakers, exhibitors and of course you for attending this meeting. As I have said before my challenge to all delegates is to learn something new, meet someone new and see something new to advance your research. Have a great few days!

#ELRIG

Drug Discovery 2019 Session Chairs

Cellular Models of Disease

Paul Andrews(University of Dundee)

Robert Vries(Hubrecht Organoid

Technology)

Chemical biology – re-defining target tractability and therapeutic class

Marcus Bantscheff(Cellzome)

Satpal Virdee(University of Dundee)

Big Data and Artificial Intelligence

Ola Engkvist(AstraZeneca)

Hugo Ceulemans(Jansen pharmaceuticals)

Targeting Ion Channels for Drug Discovery hosted by the British Pharmacological Society

Sarah Nickolls (GlaxoSmithKline)

David Kendall (Pharmnovo)

Molecular and Cellular Imaging

Michael Hennig (leadXpro)

Hit Finding Strategies

Philip Gribbon(Fraunhofer IME Screening Port)

Rosemary Burke(Institute of Cancer

Research)

Oncology Drug Discovery hosted by Cancer Research UK

Graeme Walker (Cancer Research UK Manchester Institute)

Heather McKinnon(The Beatson Institutefor Cancer Research)

Biomarkers Strategies in Drug Discovery

Sally Price (Medicines Discovery

Catapult)

Ian Pike (Ian Pike Consulting)

Tuesday 5th November 2019 Wednesday 6th November 2019

#ELRIG

Plenary Keynote Speakers

Dr. Mene Pangalos(AstraZeneca)

“Turning science into medicine: Hot trends and the business landscape”Tuesday 5th November 2019: 09:15: Room 3A

Dr. Fiona Marshall(MSD)“Tackling diseases of ageing – the application of new approaches in drug discovery and development.”Wednesday 6th November 2019: 09:10: Room 3A

The future treatment for many of today’s diseases lies in discovering new biology, understanding and challenging scientific hypotheses, to develop novel therapies. Improving R&D productivity is critical to the success of drug discovery, with failure rates from pre-clinical development to launch often in excess of 90 percent. The advent of data science and artificial intelligence, coupled with ever more sophisticated platform technologies, such as dynamic multi-omics brings with it an expanding list of pathways and targets to pursue - and with-it new drug discovery challenges.

Exploring novel drug modalities which complement existing strengths in small molecule and biologic platforms has the potential to open new therapeutic options, and to help us prosecute drug targets traditionally viewed as intractable. Over the past few years we have made significant progress across seven additional drug discovery platforms, complementing existing capabilities in chemistry and protein engineering. These include modified mRNA therapies, antisense oligonucleotides (ASOs), oligonucleotide conjugates, bicyclic peptides, proteolysis targeting chimeras (PROTACs), anticalins and CRISPR.

By combining new technologies, focusing on medical understanding, challenging scientific hypotheses and driving strategic private and academic partnerships, we are making real progress in our ability to define and prosecute novel treatment approaches for a variety of difficult to treat diseases.

Populations around the world are increasing in age and this is leading to a rise in the incidence of diseases associated with ageing. In particular, the number of people with neurodegenerative disease is placing a burden on families and healthcare systems. Despite many recent failures in developing treatments for dementia there is much hope for the future. New insights from genetics is increasing our understanding of key mechanisms underlying ageing and related diseases. Multiple therapeutic modalities are being evaluated to modulate genes and proteins involved in disease in human cell models. Finally, novel biomarkers and imaging techniques can be utilized to diagnose and stratify patients and to track the progression of disease. In combination these advances are set to alter future treatments for diseases of ageing.

Dr. Melanie Lee(LifeArc)

“Nurturing effective translation”Wednesday 6th November 2019: 10:20: Room 3A

Industry Insider Presentation

LifeArc has a 25-year legacy of collaborating with scientists, academics and industry on diagnostics and therapies, enhancing and protecting innovation, and advancing promising research. We have been enormously successful in these endeavours. But the world we deliver products into doesn’t stand still. Healthcare, science and technology are ever-changing, and this applies to translation as well. In the future, pharmaceutical companies will still need well prepared, validated therapeutic opportunities. But to be differentiated, the products will need to carry more information than they have in the past. Diagnostics will be able to identify much earlier those patients at likelihood of developing a condition. Advances in data analytics and genomic information will enable greater targeting of medicines to a sub-set of patients. How do we nurture effective translation as the world of digital informatics rapidly evolves?

#ELRIG

Connecting to Free WI-FI at ACC, Liverpool

Download the free ELRIG app and access all our conference information, programme and more from your phone or tablet.

• View the event programme• View presentation and poster abstracts • View speaker profiles• View the exhibitor guide• View the delegate and exhibitor list• Organise your day with your own favourites list• Share your profile as vCard and QR Code and scan

exhibitor QR code information tags.• Network – contact delegates, other exhibitors and

speakers easily through opt-in directories and integration with Linked-In, Twitter and Facebook

1. Enable the wireless function on your device2. Connect to the Free_Wifi SSID (wireless network)3. Browse to a web site of your choice e.g. www.accliverpool.com4. You will be re-directed to the ACC Liverpool Landing Page5. Click on the ‘FREE WI-FI ACCESS’ button6. The page of your choice will then load.

ELRIG Mobile App

Information for Participants

Registration

Registration will take place on the ground floor. Please collect your name badge and event programme from the registration desk. For security reasons it is essential to wear your badge at all times whilst attending Drug Discovery 2019.

Attendees will not be allowed access to any lecture theatre or the exhibition area without a name badge. The registration desk will open during the following times:

Tuesday 5th November: 08:00–16:30Wednesday 6th November: 08:00–14:00

You can download the ELRIG app by visiting the app store appropriate to your tablet or smart phone, scanning the QR code below or visiting the ELRIG website:

www.elrig.org/mobile-app/

Awards at Drug Discovery 2019

ELRIG Early Career Professional Impact Award sponsored by

Award Presentation: Tuesday 5th November 08:50 - 09:05Room 3A Winner Talk: Wednesday 6th November 12:20 - 12:40Room 3A

SelectScience Seal of Quality AwardsAward Presentation: Tuesday 5th November 17:15 - 17:45Training zone in exhibition hall

Cancer Research UK Oncology Poster AwardAward Presentation: Wednesday 6th November 16:00 - 16:15Room 3A

ELRIG Innovation AwardAward Presentation: Wednesday 6th November 16:15 - 16:30Room 3A

Drug Discovery 2019 Technology PrizeAward Presentation: Wednesday 6th November 16:15 - 16:30Room 3A

Drug Discovery 2019 Poster PrizeAward Presentation: Wednesday 6th November 16:15 - 16:30Room 3A

#ELRIG

ACC, Liverpool Floor plan

Exhibitor Booth LocationsacCELLerate GmbH D10Admescope A5Analytik Jena AG H6Andrew Alliance G5Applied Scientific Technologies UK Ltd B8Aptamer Group Limited H8Ardigen - on hold B4Astech Projects Ltd E6Aurelia Biosciences F9Beckman Coulter Life Sciences & Labcyte Inc J1BioAsent H5Bioivt B5Bio-Rad Laboratories Ltd G15BioStrata A2BioTek Instruments Ltd C1BlueCatBio GmbH D5BMG LABTECH Ltd G13British Pharmacological Society B2Brooks Lifesciences G10Cambridge Bioscience E4CAS A1CBRE Integrated Laboratory Solutions F8Cell Signaling F7ChemoMetec C9Cisbio G7

CRB Discovery H1Creoptix AG H2Cancer Research UK G4CytoSmart Technologies B.V. H4Dispendix A3Eurofins Discovery G6Fluidic Analytics F4Fluidigm UK Limited F6Formulatrix, Inc. C5GC biotech G11Genedata AG G1Greiner Bio One D3Hamamatsu Photonics UK Ltd B14Hamilton Bonaduz AG B9 HighRes Biosolutions Ltd F5I&L Biosystems UK LTD H7INTEGRA Bioscience Ltd E8Labcyte Inc & Beckman Coulter Life Sciences J1LabLogic Systems Limited D1LGC - ATCC E10LifeArc G12LightOx B16Medicines Discovery Catapult F2Merck A6Metrion Biosciences Ltd G16Miltenyi Biotec Ltd B3Mimetas B.V. A4

NanoTemper Technologies B12National Physical Laboratory B1Nexcelom Bioscience Ltd B7PAA F3Pelago Bioscience AB E3Promega UK Ltd F1Proteome Sciences Plc G3Reaction Biology Corporation D2Repositive B13REPROCELL D9RxNet G2Sarstedt Ltd D6Sartorius Stedim Biotech C6 Sphere Fluidics Limited D8STEMCELL Technologies B10Stratech Scientific Ltd C2Sygnature Discovery B11 Synthago H3Taconic E11Tecan UK Ltd E1 Thermo Fisher Scientific C3Tissue Solutions D4Titian Software Ltd D7Twist Bioscience B15UPM-Kymmene Corporation E7XenoGesis Ltd G8Zinsser Analytic GmbH A7

#ELRIG

ACC Exhibition Hall 2 Floor plan

#ELRIG

Media Zone Booth LocationsCamBioScience MZ1Drug Discovery News MZ5Drug Discovery World MZ6Drug Target Review MZ4SelectScience MZ7Technology Networks MZ3UK Pharmacogenetics & Stratified Medicine Network MZ8Zyme Communications MZ2

Innovation Zone Booth LocationsAtelerix Ltd IZ8BioMedha Limited IZ10British Society for Nanomedicine IZ12Cell & Soft IZ3Cell Guidance Systems IZ1Cellbox Solutions IZ2Cytomos Limited IZ6Enzymlogic IZ7Imrali Inventions IZ11innoVitro GmbH IZ9Manchester BIOGEL IZ13Microlight3D IZ4ScreenIn3D IZ14Stream Bio Ltd IZ5

Career Zone Booth LocationsGlaxoSmithKline CZ1Langton Howarth CZ2

What’s On at Drug Discovery 2019

Drug Discovery 2019 is free-to-attend:ELRIG are proud to offer free to attend scientific meetings & networking events across the UK & Europe

World class speakers:Our speakers are leading experts in their fields who will be discussing cutting edge research over the 2 days.

Innovation Zone:ELRIG supports fledgling biotech companies, who will be exhibiting their latest technologies in the Innovation Zone

Training & Workshops:Free to attend training courses on the latest scientific techniques and workshops on practical aspects of ground breaking technologies and techniques

Learning Paths:Follow our suggested agendas through the meeting to learn as much as possible about some of the hottest topics in Drug Discovery!

Early Career Professional Development:For those starting their careers in drug discovery, networking sessions, panel discussion and Workshop.

Networking Events:Meet up with 1200 fellow Drug Discovery practitioners at our network event

Vendor Exhibition:Visit our vendor exhibition in the main exhibition hall to discuss the latest products on the market

#ELRIG

Early Career Professionals

Careers in Drug Discovery: Where to next?Tuesday 5th November14:00 - 15:00Room 11B

Are you a post-doc, postgraduate, early career researcher or professional (ECP) scientist looking to start or build your career in drug discovery? If so, understanding the wide array of opportunities and career paths for you beyond academia, and how to make that step, is critical to your success.

Join us at our ECP panel discussion event:

• Hear panellists discuss and share their experiences and personal stories in making this transition

• Increase awareness of different roles and career paths in the drug discovery industrial community

• Learn more about career and professional development support available to you

• Meet other ECP scientists & expand your network• Prepare for the next exciting step in your career!

Chair:Andrew Whale (Immunocore)

Panellists:Lois Manton-O’Byrne (SelectScience)Sarah Major (Charnwood Molecular)Siobhan Leonard (LifeArc)Matthew Tomlinson (Sartorius)

Careers in Drug Discovery: Network like a bossTuesday 5th NovemberCareer & Innovation Zone17:30 - 18:30

Are you a post-doc, postgraduate, early career researcher or professional (ECP) scientist looking to start or build your career in drug discovery? If so, building and managing your network of contacts is critical to your success.

We invite you join us at our ECP speed networking event at ELRIG Drug Discovery 2019, Europe’s largest free to attend Drug Discovery conference

• Speed meet 1:1 with selected representatives across the drug discovery community, including pharma, biotech, CROs, non-for profit and more

• Learn how to network effectively• Increase your awareness of roles and career paths

in industry, academia and beyond• Expand your list of contacts and potential future

employers• Open new doors to an exciting future

Careers in Drug Discovery: Your CV for IndustryWednesday 6th November11:00 - 12:30Room 11B

Are you a post-doc, postgraduate, early career researcher or professional (ECP) scientist looking to start or build your career in drug discovery? If so, writing a compelling, industry relevant curriculum vitae is critical to maximize your chance of success.

Join us at our ECP CV workshop event:

• Learn from industry hiring managers, employer internal recruiters and recruitment consultants as to the key requirements of your CV

• Get practical advice and feedback on your CV and optimize to be ‘industry appropriate’

• Meet other ECP scientists & expand your network• Prepare for the next exciting step in your career!

As an Early Career Professional, with 50 free-to-attend talks, workshops and technical training sessions, Drug Discovery 2019 is THE place to learn about some of the hottest topics in life science research. Follow our suggested learning paths and plan your Drug Discovery experience. This year’s learning paths are:

Drug Discovery 2019 Learning Paths: Your Learning Experience Starts Here

NeuroscienceCancerNon-Small Molecule

Approaches

#ELRIG

Drug Discovery 2019 Training Zone

Throughout the two days, CamBioScience will be running a series of virtual lectures and training sessions in the training zone using silent disco and virtual reality technology. No pre-booking is necessary. Just select a time (you will find these listed after the workshops) and turn up!

Drug Discovery 2019 Learning Paths

Non-Small Molecule Approaches Cancer Neuroscience5 Nov 11:00 - 11:30

Room 3B: 5 Nov 11:00 - 11:30

Room 3B: 5 Nov 11:30 - 12:00

Room 3A:

Structure-based PROTAC design for drugging undruggable

cancer targetsProfessor Alessio Ciulli

(University of Dundee)

Structure-based PROTAC design for drugging undruggable

cancer targetsProfessor Alessio Ciulli

(University of Dundee)

Accelerating drug discovery for glioblastoma: the convergence of patient derived models, CRISPR

engineering and phenotypic screeningProfessor Steven Pollard (University of Edinburgh)

5 Nov 11:30 - 12:00Room 3B:

5 Nov 14:00 - 14:30Room 3B:

6 Nov 14:00 - 14:30Hall 1C:

Diverse binding modes for a single interface: a case study in de novo cyclic peptide binding to the BET

bromodomainsLouise Walport

(The Francis Crick Institute/Imperial College London)

Chemical targeting of deubiquitinating enzymes

for cancer therapySara Buhrlage

(Dana-Farber Cancer Institute)

GABAA Receptor Subtype Selective Compounds – Where Are We Now?

Professor John Atack (Medicines Discovery Institute)

5 Nov 16:00 - 16:30Hall 1B:

5 Nov 14:45 - 15:15Room 3A:

5 Nov 16:00 - 16:30Room 3B:

Using structural information to aid in-silico therapeutic design in the era of immunoglobulin repertoire sequencing

Professor Charlotte Deane (Department of Statistics,

University of Oxford)

3D imaging reveals effective killing of breast tumor organoids

by engineered T cells at a single cell level

Florijn Dekkers (Princess Máxima Centre)

Activity-Based Analyses of Ubiquitin E3 Ligases

Satpal Virdee (University of Dundee)

5 Nov 16:30 - 17:00Room 3B:

6 Nov 11:05 - 16:15Hall 1C:

5 Nov 16:30 - 17:00Hall 1C:

Understanding and Manipulating Protein-Protein Interactions Using

Chemical Biology ApproachesDavid Andrews (AstraZeneca)

Cancer Research UK are hosting a full track

Oncology in Drug Discovery on day 2 of the conference

Translational Neuroscience for Ion ChannelsJohn Hutchison

(Autifony)

6 Nov 14:30 - 15:00Room 3B:

Disease progression in neurodegeneration: unravelling novel biomarkers and therapeutic targets in

amyotrophic lateral sclerosisAndrea Malaspina

(Blizard Institute, Queen Margaret University, London)

6 Nov 15:15 - 15:45Room 3A:

Nanoanalytics and imaging methods in Parkinson Disease

Matthias Lauer (F. Hoffmann - La Roche Ltd)

#ELRIG

Drug Discovery 2019 Workshops

Brooks Life Sciences and Titian Software Workshop: Increase sample processing efficiency and protect sample integrity with full data visibility and inventory managementTuesday 5th November11:00 - 12:00Room 11A

Modern day drug discovery and biobanking applications involving both biological and compound samples, often requiring automated temperature-controlled storage to protect sample integrity and improve the efficiency of sample processing. These systems protect the chain of condition, identity and custody of sample collections but any connected sample data in a LIMS or Inventory Management system is usually separately managed.

In this workshop we will discuss the benefits of a combined inventory management system that controls sample ordering and integrates directly with automated storage and other equipment to track the inventory to track location, temperature and sample meta data in one central system.

Presenters:

Torsten Haensel (Technical Applications Specialist, Brooks Life Sciences)

Toby Winchester (Automation Product Manager, Titian Software)

#ELRIG

British Society of Nanomedicine Workshop: Enhancing therapeutics - a nano approachTuesday 5th November11:00 - 12:30Room 11C

This workshop, led by The British Society for Nanomedicine, will detail current approaches to enhancing therapeutic efficacy using a nanomedicine approach and is aimed at those interested in recent developments in research, manufacturing and evaluation of nanomedicines. The British Society for Nanomedicine is the UK advocate for the development and application of nanomedicines across academic and industrial sectors, bringing together and coalescing this continually growing field. The workshop is designed for new entrants to the nanomedicine field, delivering critical knowledge in a number of the key areas.

Agenda11:00 – 11:15 Welcome & BSNM & nanomedicine overview

Andrew Owen (Liverpool University)11:15 – 11:35 Developing exosomes and antibody drug

conjugates for cancer therapySteve Conlan (Swansea University)

11:35 – 11:55 Long Acting In Situ Forming Drug Delivery using Responsive NanogelsTom McDonald (Liverpool University)

11:55 – 12:15 Automation leads to accelerated optimization of lipid nanoparticles for mRNA deliveryKristina Friis (AstraZeneca)

11:15 - 12:30 Open discussion of industry – academia partnerships for translational nanomedicine

Sartorius Workshop: Live-cell analysis in combination with flow cytometry: Enhancing biological insight Tuesday 5th November11:00 - 12:20Room 11B

To enable a greater understanding of disease and potential therapy, researchers are seeking more translational assays to better describe the clinical situation. To meet these requirements has resulted in an increase in model complexity with the introduction of advanced co-culture models in both 2D and 3D. To compliment this increased complexity has been the demand to extract deeper content from these models, whilst maintaining throughput and ease of use.

In this workshop, we will discuss the latest developments in live-cell analysis and how this can be combined with flow cytometry readouts to enhance biological understanding. Through a CRO end-user case study presentation, the use of these workflows in therapeutic

Agenda11:00 – 11:05 Welcome & introductions

Nicola Bevan (Sartorius)11:05 – 11:35 Driving preclinical bioscience using iQue

Screener and IncuCyte platformsAdam Peall (Sygnature Discovery)

11:35 – 12:05 Use of combined iQue/IncuCyte workflows, enhanced data analytics and 3D invasionNicola Bevan (Sartorius)

12:05 – 12:10 Concluding remarks

discovery projects will be reviewed. Further updates will include the evolution of immune cell killing assays looking at enhanced data analytics and tumour-spheroid invasion analyses. Interactive discussions will be encouraged to explore how live-cell analysis is best aligned with discovery project requirements and how they can be further developed to address unmet need.The workshop is targeted toward researchers with general interest in translational cell models, cell-based assays, cancer biology and immunology, including current and prospective users.

SiLA Workshop: Simplification in the laboratory: how the next generation of robotics will help you in the lab Wednesday 6th November09:00 – 12:30 Room 11C

While the mainstay of laboratory has been the liquid handler, recent developments in robotics are emerging from other industries. These have led to off-loading of complex and demanding tasks onto the robot promoting operators to supervisory roles. This workshop will showcase some of the recent progress and thinking in robotics for the lab, to improve productivity, quality and innovation.

Agenda09:00 – 09:10 Welcome & Introduction

Patrick Courtney (Director, SiLA)09:10 – 09:30 Vision: How to load the dice when

approaching innovation with RoboticsDavid Swan (Robotics & Autonomous Lead,Tharsus Group UK)

09:30 – 09:50 Application: How will a robot perceive, reason and act at a chemistry lab? A perspective of embodied AIShan Luo (Dept. Computer Science, Liverpool University)

09:50 - 10:10 Technology: Benefits of mobile robots & on-demand automation in R&D labsOskari Vinko (Unitelabs, Basel)

10:10 - 10:30 Discussion panel: Automation in the lab

10:30 - 11:00 COFFEE11:00 - 11:20 User view: Revolutionising Bench

Formulation in the Manual LaboratoryMark Auty (Unilever / MIF Liverpool) & Richard Willingham (Applied Scientific Technologies)

11:20 - 11:40 Technology: New grippers for old platesMichael Köppl (i-gripper Germany)

11:40 - 12:00 Technology: When Remote Manipulation Meets Pharma Radhika Gudipati (Shadow Robot)

12:00 - 12:20 Discussion panel: Connecting it all together

12:20 - 12:30 Summing up & workshop close


#ELRIG

Charles River Laboratories Workshop: Navigating your journey from HTS to MOATuesday 5th November16:00 - 17:00Room 11A

Learn how to achieve your goals using a collaborative process, innovative science and robust technology platforms.

Beckman Coulter Life Sciences & Labcyte Inc Workshop: How Echo® Acoustic Liquid Handling Can Improve Your Drug Discovery WorkflowsTuesday 5th November14:00 - 15:00Room 11A

Presenter: John Lesnick (Labcyte Inc.)

A greater emphasis on looking back will provide fruitful direction toward discovering the drugs of the future. Acoustic liquid handling is well established at the head of traditional drug discovery funnels / pipelines through sample management and screening. Implementing acoustic liquid handling toward target identification, validation and precision medicine can enable learning from the design, build, test cycle of drug discovery.

Agenda16:00 – 16:20 Delivering HTS campaigns

collaboratively David Cronk, Mark Wigglesworth (AstraZeneca) & Philip Kelly (Charles River Laboratories)

16:20 – 16:35 Phenotypic Screening and Compound Capture Mass SpectrometryMarta Stebbeds & Diarmuid Kenny (Charles River Laboratories)

16:35 – 16:45 Biochemical Mechanism of ActionDavid Whalley (Charles River Laboratories)

16:45 - 17:00 Q & A’s

Alderley Park Accelerator Workshop: A new shared-risk partnership model at Alderley Park for developing and commercialising oncology innovations (Academia, Industry, SMEs, Specialist CROs, Incubator/Accelerator)Wednesday 6th November15:00 – 16:00Room 11B

Developing and commercialising new oncology medicines, biomarkers and models requires a multi-disciplinary, collaborative approach. At Alderley Park, we are developing a novel, shared-risk, collaborative national partnership across Academia, Industry, Specialist CROs, SMEs and the Alderley Park Incubator/Accelerator to identify, de-risk and accelerate the commercialisation of new therapies and technologies that will improve outcomes for cancer patients in the UK.

PAA Workshop: High Value Research with Low Cost Automation Wednesday 6th November11:00 – 12:00 Room 11A

Tuesday 5th November

Cerebral OrganoidsListen to a virtual lecture by Dr Madeline Lancaster (University of Cambridge), giving an overview of brain development and an introduction to cerebral organoids. This lecture will be repeated throughout the day at the following times:

10:05-10:5012:30-14:0015:30-16:00

CRISPR BasicsCome and listen to our course instructors virtual lecture, giving an overview of the CRISPR basics.

12:00-12:30 Introduction to CRISPR Dr Oliver Baker (King’s College London)

14:45-15:15 Introduction to genetically modified mouse models. Dr Ben Davis (University of Oxford)


Agenda11:00 – 11:15 Welcome & Introduction

Malcolm Crook (Technical Director PAA)

11:15 – 11:30 Drug Discovery with Hidex plate imager & S-LAB plate handlerTrevor Askwith (UCL School of Pharmacy)

11:30 – 11:35 Q & A’s11:35 - 11:50 Using flow cytometry and automation

Farah Mughal (Research Project Specialist, Dept of Biochemistry, University of Liverpool) & Srijan Jindral (University of Manchester)

11:50 - 11:55 Q & A’s11:55 - 12:00 Workshop close

Malcolm Crook (Technical Director PAA)

Wednesday 6th November

Cerebral OrganoidsListen to a virtual lecture by Dr Madeline Lancaster (University of Cambridge), giving an overview of brain development and an introduction to cerebral organoids. This lecture will be repeated throughout the day at the following times:

10:20-10:4012:50-14:00

CRISPR BasicsCome and listen to our course instructors give an overview of the CRISPR basics. Oliver will introduce CRISPR and Ben will give an introduction to genetically modified mouse models.

11:00-11:50 Introduction to CRISPR & genetically modified mouse models. Dr Oliver Baker (King’s College London) & Dr Ben Davis (University of Oxford)

#ELRIG

Drug Discovery 2019 Training ZoneIn assossication with:

Cellular Models of DiseaseTuesday 5 November 2019: Room 3A

Track Summary:

High attrition rates in drug development, need new approaches to therapeutic discovery, and we especially need preclinical models that faithfully represent patients. The identification of adult stem cells and methods to grow them into so called ‘organoids’, as well as directed differentiation of embryonic stem cells, patient-derived iPSC technology and precision genome engineering have transformed our ability to generate myriad cell types in both the diseased and healthy states and recapitulate at least some aspects of disease in vitro. Recent studies have shown that these patient derived models are directly representing the clinical responses of the associated patients. In addition, the advent of 3D culture in vitro is now opening up the possibility of near-physiological tissue organisation that increasingly is resembling other aspects of the native function. These new models represent a powerful in vitro platform for preclinical drug discovery and validation, as well as finally allowing the long-term promise of personalized medicine, topics which will be discussed in this session.

#ELRIG

08:00 - 08:45 REGISTRATION08:45 - 08:55 ELRIG Annual Review, Steve Rees (ELRIG Chairman)08:55 - 09:05 Early Career Professionals Overview, Del Trezise (ELRIG ECP Workgroup Leader)09:05 - 09:15 Conference & Plenary Keynote Introduction, Katy Kettleborough (LifeArc)09:15 - 10:05 PLENARY KEYNOTE:

Turning science into medicine: Hot trends and the business landscapeMene Pangalos (AstraZeneca)

10:05 - 10:50 COFFEE10:50 - 11:00 Session Chairs Introduction

Paul Andrews (National Phenotypic Screening Centre) & Robert Vries (Hubrecht Organoid Technology) 11:00 - 11:30 What goes around comes around in drug discovery: from organs to targets and back again

Paul Andrews (National Phenotypic Screening Centre)11:30 - 12:00 Accelerating drug discovery for glioblastoma: the convergence of patient derived models,

CRISPR engineering and phenotypic screeningProfessor Steven Pollard (University of Edinburgh)

12:00 - 12:30 PLATINUM SPONSOR PRESENTATION: Automation meets cell separation: primary cells for drug discovery assays

Lotta Räty (Miltenyi Biotec Ltd)12:30 - 14:00 LUNCH & POSTERS14:00 - 14:30 Organoids: A Patient in the lab

Robert Vries (Hubrecht Organoid Technology)14:30 - 14:45 Poster Spotlight: Morphometric imaging of organoids for toxicology & assessment of therapeutic

efficacy, Brent Ryan (National Physical Laboratory)14:45 - 15:15 3D imaging reveals effective killing of breast tumor organoids by engineered T cells at a single cell level

Florijn Dekkers (Princess Máxima Centre)15:15 - 15:30 Poster Spotlight: Morphometric imaging of organoids for toxicology and assessment of therapeutic

efficacy, James Noble (National Physical Laboratory)15:30 - 16:00 COFFEE16:00 - 16:30 Reducing attrition in drug discovery through the use of human translational cellular models

Wendy Rowan (GlaxoSmithKline) 16:30 - 17:00 CRISPR/Cas-assisted genetics in intestinal organoids

Bon-Kyoung Koo (IMBA - Institute of Molecular Biotechnology of Austrian Academy of Sciences)17:00 - 19:00 DRINKS RECEPTION & POSTERS

Session Chairs: Paul Andrews (National Phenotypic Screening Centre) & Robert Vries (Hubrecht Organoid Technology)

Publication date 22/10/2019. More detail, abstracts, speaker biogs, etc, are available on our website www.elrig.org or our mobile app ‘ELRIG’

Platinum Sponsor track:

Chemical biology – re-defining target tractability and therapeutic classTuesday 5 November 2019: Room 3B

Track Summary:

In recent years chemical biology approaches have re-defined therapeutic class and chemical tractability of proteins. Notably, event-driven pharmacology and novel classes of therapeutics offer great promise for targets previously considered undruggable. In this session exciting new concepts in chemical biology and opportunities for drug discovery with tangible potential to improve patient health will be discussed.

Session Chairs: Marcus Bantscheff (Cellzome A GSK company) & Satpal Virdee, (University of Dundee)

Publication date 22/10/2019. More detail, abstracts, speaker biogs, etc, are available on our website www.elrig.org or our mobile app ‘ELRIG’

08:00 - 08:45 REGISTRATION08:45 - 08:55 ELRIG Annual Review, Steve Rees (ELRIG Chairman)08:55 - 09:05 Early Career Professionals Overview, Del Trezise (ELRIG ECP Workgroup Leader)09:05 - 09:15 Conference & Plenary Keynote Introduction, Katy Kettleborough (LifeArc)09:15 - 10:05 PLENARY KEYNOTE:


10:05 - 10:50 COFFEE10:50 - 11:00 Session Chairs Introduction, Marcus Bantscheff (Cellzome A GSK company) & Satpal Virdee,

(University of Dundee)11:00 - 11:30 Structure-based PROTAC design for drugging undruggable cancer targets

Professor Alessio Ciulli (University of Dundee) 11:30 - 12:00 Diverse binding modes for a single interface: a case study in de novo cyclic peptide binding to the BET

bromodomainsLouise Walport (The Francis Crick Institute/Imperial College London)

12:00 - 12:15 Poster Spotlight: LifeArc Index Set: Utility for assessing target tractability and performance in a pheno-typic screen, Afrah Sattikar (LifeArc)

12:15 - 12:20 Technology Spotlight: Diarmuid Kenny (Charles River Laboratories) 12:20 - 12:25 Technology Spotlight: Craig Malcolm (Promega UK Ltd)12:25 - 12:30 Technology Spotlight: Carol Austin (Eurofins Discovery)12:30 - 14:00 LUNCH & POSTERS14:00 - 14:30 Chemical targeting of deubiquitinating enzymes for cancer therapy

Sara Buhrlage (Dana-Farber Cancer Institute)14:30 - 14:45 Poster Spotlight: Development of affinity and fluorescent probes to elucidate the mechanism of small

molecule modulators of neurogenesis, Rachel Sim (University of Oxford)14:45 - 15:15 Towards Next Generation Chemical Probes

Keriann Backus (UCLA) 15:15 - 15:20 Technology Spotlight: Devin Donnelly (Beckman Coulter Life Sciences & Labcyte Inc.)15:20 - 15:25 Technology Spotlight: Hugo Viana (Merck)15:25 - 15:30 Technology Spotlight: Louise Affleck (Cisbio)15:30 - 16:00 COFFEE16:00 - 16:30 Activity-Based Analyses of Ubiquitin E3 Ligases

Satpal Virdee (University of Dundee) 16:30 - 17:00 Understanding and Manipulating Protein-Protein Interactions Using Chemical Biology Approaches

David Andrews (AstraZeneca) 17:00 - 19:00 DRINKS RECEPTION & POSTERS

#ELRIG

Track Sponsor:

Artificial Intelligence (AI) is now being applied everywhere including drug discovery. In this session we would like to give the audience a sense of what is going on in applying AI and machine learning (ML) in drug discovery by covering several important aspects. The background and historical development of ML and AI in drug discovery will be presented. We will also take a look at the most important ingredient to successfully apply ML and AI in drug discovery project, namely the data and how it can be integrated. Applying ML to large datasets is an important topic that pushes the current machine learning algorithms to the limit. Another important topic to be covered is the integration of ML/AI with automation and the sizeable synergy effects when combining them. Finally, application of deep learning in drug design has now become common, so it is time to hear from a medicinal chemist expert if there has been any real impact on the drug design process or if it just has been another hype.

Big Data and Artificial IntelligenceTuesday 5 November 2019: Hall 1B

Track Summary

Session Chairs: Ola Engkvist (AstraZeneca) & Hugo Ceulemans (Janssen Pharmaceutica)

08:00 - 08:45 REGISTRATION08:45 - 08:55 ELRIG Annual Review, Steve Rees (ELRIG Chairman)08:55 -09:05 Early Career Professionals Overview, Del Trezise (ELRIG ECP Work group Leader)09:05 - 09:15 Conference & Plenary Keynote Introduction, Katy Kettleborough (LifeArc)09:15 - 10:05 PLENARY KEYNOTE:



Ola Engkvist (AstraZeneca) & Hugo Ceulemans (Janssen Pharmaceutica) 11:00 - 11:30 Artificial Intelligence: the story so far and the next chapter for drug discovery

Sam Genway (Tessella) 11:30 - 12:00 Development of FAIR data methods in Life Science and Drug Discovery research

Philip Gribbon (Fraunhofer IME ScreeningPort)12:00 - 12:15 Poster Spotlight: Discovering Novel Therapeutic Targets Using Large Biomedical Knowledge Graphs

Arwa Raies (European Bioinformatics Institute (EMBL-EBI))12:15 - 12:20 Technology Spotlight: Evelyne Ploquin (Thermo Fisher Scientific)12:20 - 12:25 Technology Spotlight: Cameron Scott (Genedata AG)12:25 - 12:30 Technology Spotlight: Jonathan Agbenyega (CAS)12:30 - 14:00 LUNCH & POSTERS14:00 - 14:30 Embedding Machine Learning into Medicinal Chemistry – Application of Neural Networks in Real Life

Drug Discovery ProjectsWerngard Czechtizky (AstraZeneca)

14:30 - 14:45 Poster Spotlight: Expression Data Integration: Advancing Immuno-Oncology Target DiscoveryFrank Staubli (Nebion AG)

14:45 - 15:15 Data Science and AI approaches to Drug Target Validation and repurposingProfessor Michael Barnes (Centre for Translational Bioinformatics, William Harvey Research Institute, Queen Mary University of London)

15:15 - 15:20 Technology Spotlight: Stina Lundgren (Pelago Bioscience AB)15:20 - 15:25 Technology Spotlight: Mark Wigglesworth (AstraZeneca, SLAS)15:25 - 15:30 Technology Spotlight: Mark Graham (GE Healthcare)15:30 - 16:00 COFFEE16:00 - 16:30 Deep Generative Models for 3D Compound Design

Professor Charlotte Deane (Department of Statistics, University of Oxford)16:30 - 17:00 AI(d) in navigating small molecule space

Hugo Ceulemans (Janssen Pharmaceutica) 17:00 - 19:00 DRINKS RECEPTION & POSTERS

#ELRIGPublication date 22/10/2019. More detail, abstracts, speaker biogs, etc, are available on our website www.elrig.org or our mobile app ‘ELRIG’

Drugs targeting ion channels are an important component of many medicine cabinets, but over the past 10-15 years active programs targeting ion channels in the pharmaceutical industry have fallen and a perception may exist that these are difficult proteins to drug. However, significant progress in understanding ion channel pharmacology and structure is being made, which leads us to suggest that this target class is currently being under exploited. Therefore, in this symposium we will look at some of the recent progress in targeting ligand and voltage gated ion channels in disease.

Track Sponsor:

Targeting Ion Channels for Drug DiscoveryTuesday 5 November 2019: Hall 1C

Track Summary

Session Chairs: Sarah Nickolls (GlaxoSmithKline) & David Kendall (Pharmnovo)

08:00 - 08:45 REGISTRATION08:45 - 08:55 ELRIG Annual Review, Steve Rees (ELRIG Chairman)08:55 - 09:05 Early Career Professionals Overview, Del Trezise (ELRIG ECP Work group Leader)09:05 - 09:15 Conference & Plenary Keynote Introduction, Katy Kettleborough (LifeArc)09:15 - 10:05 PLENARY KEYNOTE:



Sarah Nickolls (GlaxoSmithKline) & David Kendall (Pharmnovo)11:00 - 11:30 Activation of mechanosensitive TREK potassium channels – a therapeutic strategy for the treatment of pain

Professor Alistair Mathie (University of Kent) 11:30 - 12:00 Screening for activators of K2P channels - A target class approach to identify novel analgesics

Paul Wright (LifeArc) 12:00 - 12:10 Poster Spotlight: A Higher-Throughput Approach to Investigate Cardiac Contractility In Vitro Under

Physiological Mechanical ConditionsMatthias Gossmann (innoVitro GmbH)

12:10 - 12:30 INDUSTRY INSIDER PRESENTATION: Potent and selective state-dependent Cav2.2 calcium channel

modulators with efficacy in preclinical pain models and human tissue Marc Rogers (Metrion Biosciences Ltd)

12:30 - 14:00 LUNCH & POSTERS14:00 - 14:30 GABAA Receptor Subtype Selective Compounds – Where Are We Now?

Professor John Atack (Medicines Discovery Institute) 14:30 - 14:45 Poster Spotlight: Ligand-gated ion channels involved in pain pathways: An automated patch clamp study

Alison Obergrussberger (Nanion Technologies GmbH) 14:45 - 15:15 Targeting voltage-gated calcium channels in disease

Professor Gary Stephens (University of Reading) 15:15 - 15:20 Technology Spotlight: Juha Kammonen (Charles River Laboratories)15:20 - 15:25 Technology Spotlight: Dan Lord (Formulatrix)15:25 - 15:30 Technology Spotlight: Joe Lackey (LGC)15:30 - 16:00 COFFEE16:00 - 16:30 A story of collaboration: Ion Channels for Drug Discovery

Kelly Gatfield (GlaxoSmithKline) 16:30 - 17:00 Translational Neuroscience for Ion Channels

John Hutchison (Autifony)17:00 - 19:00 DRINKS RECEPTION & POSTERS

Hosted by:

Publication date 22/10/2019. More detail, abstracts, speaker biogs, etc, are available on our website www.elrig.org or our mobile app ‘ELRIG’#ELRIG

Molecular and Cellular ImagingWednesday 6 November 2019: Room 3A

Session Summary:

Session Chair: Michael Hennig (leadXpro AG)

Visualization of biological structures has been of great impact to the understanding of biological mechanisms including drug action. This session covers a number of cutting-edge technologies to facilitate the structure determination from small molecules (chemical compounds by electron diffraction of nano-crystals) to large biological complexes with drug candidates investigated by X-ray crystallography and cryo-Electron Microscopy. Time resolved and multi-conformation analysis gives insight into drug binding and associated molecular dynamics visualizing pharmacological response. Extension of the methods to the imaging of cells by cryo-EM tomography and Mass spectroscopy will give exciting new perspectives for the understanding of diseases.

08:00 - 09:00 REGISTRATION09:00 - 09:10 Welcome & Introduction to Plenary Keynote, Tim Hammonds (Cancer Research UK)09:10 - 10:00 PLENARY KEYNOTE:

Tackling diseases of ageing – the application of new approaches in drug discovery and developmentDr Fiona Marshall (MSD)

10:00 - 10:20 INDUSTRY INSIDER PRESENTATION: Nurturing effective translation

Melanie Lee (LifeArc)10:20 - 11:00 COFFEE 11:00 - 11:10 Session Chairs Introduction

Michael Hennig (leadXpro AG) 11:10 - 11:40 CRYO-EM and X-RAY free electron laser enabled structure based drug discovery on challenging mem-

brane protein targetsMichael Hennig (leadXpro AG)

11:40 - 11:45 Technology Spotlight: Suzanne Riches (Nexcelom)11:45 - 11:50 Technology Spotlight: Antoine Fouillet (BioTek Instruments Ltd)11:50 - 12:20 Electron diffraction of 3D protein crystals

Emma Beale (Diamond Light Source Ltd)12:20 - 12:40 ELRIG ECP IMPACT AWARD WINNER PRESENTATION:

Drug discovery data on demandThomas Fleming (Arctoris)

12:40 - 12:45 Technology Spotlight: Corné Swart (Cellbox Solutions)12:45 - 12:50 Technology Spotlight: Alistair Robertson (Tecan UK Ltd)12:50 - 14:00 LUNCH & POSTERS14:00 - 14:30 Novel opportunities for targeting metabolic regulation from imaging macromolecular assemblies

Timm Maier (Biozentrum, University of Basel)14:30 - 15:00 Mass Spectrometry - A Useful Addendum for Multimodal Imaging Pipelines?

Martina Marchetti-Deschmann (TU Wien, Institute of Chemical Technologies and Analytics)15:00 - 15:15 Poster Spotlight: Automated imaging and analysis of collective cell migration

Hiren Patel (CytoSMART Technologies B.V.) 15:15 - 15:45 Nanoanalytics and imaging methods in Parkinson Disease

Matthias Lauer (F. Hoffmann - La Roche Ltd)15:45 - 16:15 Cell geometry modulates the activation of fibroblasts in engineered 3D tumor microenvironments

Saradha Venkatachalapathy (Mechanobiology Institute, National University of Singapore)16:15 - 16:30 CONFERENCE CLOSE - Tim Hammonds (Cancer Research UK)


The use of clinical biomarkers has grown exponentially since they were first employed in the 1970s. The sequencing of the human genome and development of omics technologies have significantly accelerated the development and adoption of biomarkers in drug discovery and development, as well as clinical decision making. Biomarkers for precision medicine in oncology has probably seen the greatest benefit from this technological innovation with new developments continuing to push boundaries. Biomarkers in other disease areas are now following behind the precedent set in oncology. These are facing different challenges but have significant potential to facilitate better treatment options for patients. This session will discuss how appropriate, well validated, biomarkers will drive a reduction in drug attrition in all therapeutic areas over the next few decades.

Biomarker Strategies in Drug DiscoveryWednesday 6 November 2019: Room 3BSession Chairs: Sally Price (Medicines Discovery Catapult) & Ian Pike (Ian Pike Consulting)

Session Summary:

08:00 - 09:00 REGISTRATION09:00 - 09:10 Welcome & Plenary Keynote Introduction, Tim Hammonds (Cancer Research UK)09:10 - 10:00 PLENARY KEYNOTE:




Sally Price (Medicines Discovery Catapult) & Ian Pike (Ian Pike Consulting)11:10 - 11:40 Label-Free Imaging and its many applications

Peter O’Toole (University of York)11:40 - 11:45 Technology Spotlight: Catherine Wark (BMG Labtech Ltd)11:45 - 11:50 Technology Spotlight: Stephan Kaizik (Bio Rad)11:50 - 12:20 Supporting pathology with multimodal molecular mass spectrometry imaging:

Case studies in compound biodistribution, efficacy and safetyGregory Hamm (AstraZeneca)

12:20 - 12:35 Poster Spotlight: The Cellular Thermal Shift Assay in drug discovery: how CETSA ® MS identify targets, off-targets and biomarkers in live cells, Isabel M Caballero (Pelago Bioscience AB)

12:35 - 12:40 Technology Spotlight: Jennifer Birtwell (Hamilton Bonaduz AG)12:40 - 12:45 Technology Spotlight: Lucy Farmer (LabLogic Systems Limited)12:45 - 12:50 Technology Spotlight: Zoe Nilsson (Sphere Fluidics Limited)12:50 - 14:00 LUNCH & POSTERS14:00 - 14:30 Biomarker Strategies in Drug Discovery:

Can we Reduce Attrition and Streamline Development of Novel Anti-Fibrotics?Sally Price (Medicines Discovery Catapult) & Simon Cruwys (TherapeutAix)

14:30 - 15:00 Disease progression in neurodegeneration: Unravelling novel biomarkers and therapeutic targets in amyotrophic lateral sclerosisAndrea Malaspina (Blizard Institute, Queen Margaret University, London)

15:00 - 15:15 Poster Spotlight: Immuno-Oncology Drug Testing in Patient-Derived Microtumor/Immune Cell Models: The Added Value of Protein Profiling, Christoph Sachse (NMI TT Pharmaservices)

15:15 - 15:45 The Modern Proteomics Continuum for Biomarker Discovery, Validation and Implementation in Drug DiscoveryIan Pike (Ian Pike Consulting)

15:45 - 16:15 High sensitivity immunoassays for translational biomarker assessments: from mice to menChantal Bazenet (Evotec)

16:15 - 16:30 CONFERENCE CLOSE - Tim Hammonds (Cancer Research UK)


Hit Finding StrategiesWednesday 6 November 2019: Hall 1B

Session Summary:

Session Chairs: Philip Gribbon (Fraunhofer IME Screening Port) & Rosemary Burke (The Institute of Cancer Research)

The process of identifying small molecule hits which are suitable for subsequent optimisation into leads and eventually candidates is a critical stage of the drug discovery workflow. In this session, we will hear from industrial and academic experts on their organisations’ approaches taken to find high quality starting points for a range of biochemical targets and phenotypic readouts. Talks will cover strategies and case studies, including the use of fragment-based and biophysical readouts, experiences of new and enabling technologies, as well the systematic use of phenotypic assay formats utilising iPSC derived cellular models of disease.

Platinum Sponsor track:





Philip Gribbon (Fraunhofer IME Screening Port) & Rosemary Burke (The Institute of Cancer Research)11:10 - 11:40 How small can you go? Crystallographic screening with ultra-low

molecular weight fragments to guide drug designTom Davies (Astex Pharmaceuticals)

11:40 - 11:50 Poster Spotlight: An enabling label-free platform for RNA drug discovery using SAMDI mass spectrometry, Zachary Gurard-Levin (SAMDI Tech, Inc.)

11:50 - 12:20 Application of Sosei Heptares GPCR StaR® platform for Structure Based Drug Design & Hit IdentificationGreg Osborne (Sosei Heptares)

12:20 - 12:50 PLATINUM SPONSOR PRESENTATION: Fragment-based hit-finding strategy reveals novel

chemistry against three cancer targetsJana Wolf (NanoTemper Technologies)

12:50 - 14:00 LUNCH & POSTERS14:00 - 14:30 THOUGHT LEADER SPONSOR PRESENTATION:

Enabling Success in Lead IdentificationColin Sambrook Smith (Sygnature Discovery)

14:30 - 15:00 Hit Identification, how to start a drug discovery project rightGuillaume Mondesert (Evotec)

15:00 - 15:15 Poster Spotlight: High throughput small molecule screening for inducers of epicardial cell EMT after myocardial infarction, Sophia Malandraki-Miller (University of Oxford)

15:15 - 15:45 Finding inhibitors of transcription factor activation with phenotypic screensPaul Clarke (Institute of Cancer Research)

15:45 - 16:15 Hit finding to series validation - where are the bottlenecks?Professor David Gray (University of Dundee)



Oncology Drug DiscoveryWednesday 6 November 2019: Hall 1C

Session Summary:

Session Chairs: Heather McKinnon (Beatson) & Graeme Walker (Cancer Research UK)

CRUK is a leader in funding cancer research across the UK, supporting basic research to unravel the mechanisms by which cancer cells survive and grow. To ensure this science is rapidly and effectively translated into new treatments for patients, CRUK also funds a number of Drug Discovery Units (DDUs) to work closely with basic scientists within their institutes and across the CRUK network. These groups provide industry standard research covering all stages of the drug discovery process from early validation studies, through hit finding, lead optimisation and into clinical development. CRUK currently has more than 30 agents in pre-clinical and clinical development and six drugs already on the market being used to treat patients. In this track you will hear about a number of the projects currently being prosecuted by the drug discovery groups, taking both small molecule and antibody approaches. You will also gain an insight into the type of technology that enables drug discovery today to advance on some of the really challenging targets that are likely to have a substantial impact on cancer therapy.





Heather McKinnon (The Beatson Institute for Cancer Research) & Graeme Walker (Cancer Research UK Manchester Institute)

11:05 - 11:45 Title: Innovative cancer drug discovery: Progress, opportunities and future challengesProfessor Paul Workman (The Institute of Cancer Research, London)

11:45 - 11:50 Technology Spotlight: Nirmal Perera (LGC - ATCC)11:50 - 12:20 The Power of One: Discovery of the first selective and non-covalent small molecule inhibitors of DNMT1

Ali Raoof (Cancer Research UK Manchester Institute)12:20 - 12:25 Technology Spotlight: Sharon Barnard (INTEGRA Bioscience Ltd)12:25 - 12:50 Cancer Research UK AstraZeneca Antibody Alliance Laboratory:

Delivering therapeutic and diagnostic antibodies through collaborationMaria Groves (Cancer Research UK-MedImmune Alliance Laboratory)

12:50 - 14:00 LUNCH & POSTERS14:00 - 14:30 Innovative drug discovery alliances to maximize patient benefit in Immuno-Oncology

Stuart Farrow (CR-UK Therapeutic Discovery Laboratories) 14:30 - 15:00 Structure-based optimisation of isoindolinone MDM2-p53 inhibitors with potent in vivo activity

Ian Hardcastle (Newcastle University) 15:00 - 15:15 Poster Spotlight: The Joint AstraZeneca - Cancer Research UK Functional Genomics Centre: Driving

Drug Discovery Through Innovation In Functional Genomics ScreeningDavid Walter (Cancer Research UK–AstraZeneca Functional Genomics Centre)

15:15 - 15:45 The discovery of Novel Fascin Inhibitors and their potential role in Invasion and MetastasisStuart Francis (The Beatson Institute for Cancer Research)

15:45 - 16:15 MPS1 inhibitors and the molecular basis for resistance to MPS1 inhibitionRob Van Montfort (The Institute of Cancer Research)


Hosted by:


Drug Discovery 2019 Technology Spotlight TitlesTuesday 5th November

Wednesday 6th November

#ELRIG

Track: Chemical biology - re-defining target and therapeutic class tractability• Discovery of New Therapeutics through the fusion of small & large molecules, Diarmuid Kenny (Charles River Laboratories)• Measurement of kinase inhibitor target engagement in live-cells & mechanistic analysis of PROTAC-mediated targeted

degradation of kinase targets, Craig Malcolm (Promega)• Evolution of Contract Research Organizations to Contract Innovation Organizations? Carol Austin (Eurofins Discovery)• Beckman and Labcyte: Dawning of a new Liquid Handling Era, Devin Donnelly (Beckman Coulter Life Sciences &

Labcyte Inc.) • Partial PROTACs for Targeted Protein Degradation, Hugo Viana (Merck)• HTRF Assays for Target Biology identification and Validation in Drug Discovery, Louise Affleck (Cisbio)

Track: Big Data & Artificial Intelligence• On the way to Artificial Intelligence: Feeding data hungry Machine Learning Algorithms using Thermo Scientific

Momentum Lab Automation Systems, Evelyne Ploquin (Thermo Fisher Scientific)• Genedata Imagence® - Deep Learning Automates the Analysis of Cell Painting Assays, Cameron Scott (Genedata)• Conquer the Chaos, Jonathan Agbenyega (CAS)• Navigate the proteome with CETSA® MS, Stina Lundgren (Pelago)• SLAS’s Growing AIm in Artificial Intelligence and Big Data, Mark Wigglesworth (AstraZeneca, SLAS)• The Evolution of High Content Analysis, Mark Graham (GE Healthcare)

Track: Cellular Models of Disease• Automation meets cell separation: primary cells for drug discovery assays, Lotta Räty (Miltenyi Biotec Ltd)

Track: Targeting ion channels for drug discovery• Potent and selective state-dependent Cav2.2 calcium channel modulators with efficacy in preclinical pain models and

human tissue, Marc Rogers (Metrion Biosciences) • Realise the full potential of your ion channel targets with Charles River, David Cronk (Charles River Laboratories)• Scaling Organoid Culture using MANTIS ® Liquid Handler: A Case Study with MIT, Dan Lord (Formulatrix)• TRC: Introducing a comprehensive range of high quality research chemical’s and custom synthesis solutions,

Joe Lackey (LGC)

Track: Molecular & Cellular Imaging• CellacaTM MX: A novel instrument for high-throughput, high-speed cell counting, concentration, and viability,

Suzanne Riches (Nexcelom)• The new wide field of view Cytation 5: from cell counting to complex imaging applications,

Antoine Fouillet (BioTek Instruments)• The #CELLBOX - The Live Cell Shipper, Corné Swart (Cellbox Solutions)• Spark Cyto – Live Cell Plate Reader with Real-Time Image Cytometry, Alistair Robertson (Tecan)

Track: Biomarkers Strategies in Drug Discovery• Microplate Reader technology for Biomarker assays and discovery, Catherine Wark (BMG Labtech Ltd)• Bio-Rad Bio-Plex® Multiplex Immunoassay in Biomarker Discovery & Validation,

Stephan Kaizik (Bio-Rad Laboratories Ltd)

• Vantage: The Power Of Automation, Jennifer Birtwell (Hamilton)• Hidex Sense Multi Technology Microplate Reader and InCellis Samrt Cell Imaging System, Lucy Farmer (Lablogic)• A Revolutionary Platform for Single Cell Analysis in Drug Discovery, Zoe Nilsson (Sphere Fluidics)

Track: Hit Finding Strategies• Fragment-based hit-finding strategy reveals novel chemistry against two cancer targets, Jana Wolf (Nano-Temper)

Track: Oncology Drug Discovery• From bench to bedside: advanced ATCC cancer models for translational cancer research, Nirmal Perera (LGC)• Assist Plus, Sharon Barnard (Integra Bioscience)

The second CRISPR in Drug Discovery: From Targets to Therapeutics meeting will be held at the Babraham Institute, Cambridge, 12th and 13th February 2020. Genome Engineering, including zinc-finger nucleases, TALENs and most recently CRISPR/Cas9, has become a powerful tool in the drug discovery pipeline.

This meeting will focus on the application of genome engineering to identify novel drug targets through large scale CRISPR based functional genomics studies, developing advanced cellular and in vivo disease models for target validation, and the pioneering applications in therapeutic genome editing. A current perspective of the applications of these rapidly developing technologies with a focus on drug discovery applications will be the meeting’s focus. The scientific program for this CRISPR in Drug Discovery meeting will include:

• Large-scale CRISPR functional genomics studies for drug target identification and validation

• Application of genome engineering in developing biological models of disease from single cells through to complex in vitro tissue systems and in vivo models

• Cutting edge CRISPR genome engineering

technologies and their emerging applications

• A perspective from technology leaders toward the future therapeutic applications of genome engineering

We aim to bring together the research community working in the field of genome engineering with interests in developing and applying the technology for pharmaceutical research. Join scientists from academia, pharma, biotech, and CRO’s to hear talks given by speakers at the cutting edge of genome engineering, take part in commercial vendor lab-based workshops, network at the exhibition, innovation forum and speakers dinner and gain strategic insights into solutions for increasing the success of drug discovery and development.

The 2020 ELRIG Research & Innovation conference will discuss how the most promising new biology is being identified and explore emerging technologies and innovations to enable this science to be translated into successful therapeutics. The four scientific sessions will address different aspects of innovation in biology and discovery technologies as we move into a new decade:

CRISPR inDrug Discovery 2020From Targets to Therapeutics

Babraham Institute, Cambridge4 - 5 March 2020

The KingÕs Centre, Oxford31 March - 1 April 2020

Research &Innovation 2020Therapeutic innovation

for the new decade

Examining the prospects for structural biology and biophysics in complex and more physiological systems and in supporting the entire discovery process from target identification through to assessment of target engagement

• Innovations in structural biology & biophysics

• Seeking novel drug targets for the Discovery pipeline

• The rise of immunology across DiscoveryMoving beyond the field of immuno-oncology to explore both the rising interest in immunology-based targets in other therapeutic areas and highlight the potential of different therapeutic modalities.

Highlighting new technologies that are being developed alongside new approaches to academia-industry collaboration that are combining to build a pipeline of new targets for drug discovery.

• Good bugs / bad bugsThe first part of this session will explore the biology of the microbiome in health and disease and the prospects for microbiome-targeting drug therapies. The second part will concentrate on technical and platform innovations in the field of antibiotic discovery.

ELRIG Events 2020

#ELRIG

The first ELRIG meeting on Advances in Cell and Gene Therapies will be held on the 6th and 7th of May 2020 at the AstraZeneca R&D site in Gothenburg. This interactive 2-day conference will host world leading scientists from academia and industry to discuss current and future perspectives of Cell and Gene Therapies.

Cell and gene therapies are rapidly evolving at a fast pace, revealing many new and exciting therapeutic opportunities not previously amenable to drug discovery. We aim to bring together scientists from academia, pharma, biotech, and CRO’s to engage with speakers at the cutting edge of developing and applying cell and gene therapies.

The event will help participants develop a better understanding of the field and provide networking opportunities with a range of key experts. Our aim is to create an open and inspiring environment that will foster discussions and the identification of opportunities for collaboration with a scientific program developed around three key focus areas:

Now in its 14th year, ELRIG’s flagship conference Drug Discovery 2020 will take place at ExCeL, London. This year’s event will include cutting edge talks and examples of new directions in drug discovery. Our scientific programme will feature over 50 world-class speakers with 6 main session tracks and 2 plenary keynote speakers. The tracks for 2020 are:

Cell & GeneTherapy 2020

AstraZeneca, Gothenburg6 - 7 May 2020

ExCeL, London6 - 7 October 2020

Drug Discovery 2020

20:20 Vision - enabling discovery of new medicines

There will be numerous opportunities to network with scientists and researchers from the pharmaceutical, academic and vendor communities throughout the 2-day conference. The program also includes poster viewing sessions, a poster snapshot presentation opportunity for select posters, vendor exhibition, speaker’s dinner and tour of the Amazing Journey at AstraZeneca.

• Cell based therapies across disease areas• Recent advances in cancer gene therapies• Therapies for genetic conditions

In partnership with key academic and charitable groups, we will also run joint disease and biology-oriented tracks focusing on the basic sciences that underpin successful drug discovery.

Drug Discovery has become the largest meeting of life sciences industry professionals in the UK. This 2-day event will bring together more than 1200 delegates and over 100 exhibiting companies from around the world who will highlight the latest ground-breaking research, discuss cutting-edge advances in the application of laboratory technology to understand disease biology and to identify novel chemical and biological candidate drugs.

To maximize the interaction between delegates and exhibitors/sponsors, our programme includes scientific poster sessions, coffee/tea and lunch breaks that are located within the vendor exhibition area and a drinks/networking reception on the first day. The meeting is free-of-charge to all delegates and include complimentary refreshments and lunch. Exhibition spaces are limited so we recommend booking early to ensure a prime location.

• Innovations in Chemistry to discover new medicines

• How do we find better Hits that are more likely to translate to new therapeutics?

• New Modalities to treat disease• Multi Omic approaches to deliver new medicines• Patient relevant models for drug discovery

Infection

ELRIG Events 2020

#ELRIG

The 7th biennial Pharmaceutical Flow Cytometry and Imaging meeting will be held at GlaxoSmithKline, Stevenage, UK. Flow cytometry and imaging are two powerful technology platforms that enable high-content analysis of physiologically-relevant cell systems and pre-clinical and clinical biomarkers. Since our first meeting in 2008, we have seen the technology develop and the applications widen across many areas of industrial and academic drug discovery and development. This meeting will focus on the application of Flow Cytometry and Imaging to illuminate biology from the single cell to the patient. The scientific program for this meeting is:

Since the launch of ELRIG networking events at the end of 2016, we have hosted a series of successful meetings at various locations around the country. These are short, usually evening sessions, encouraging collaboration between local scientists from academia and pharma, biotech and technology industries. The focus is on developing solutions for unmet scientific or technical challenges and to create opportunities through this enhanced collaboration to engage in a beneficial manner in a localised environment. Each event has a different theme, and typically involves 2-3 informal presentations by invited speakers whose work is relevant to the theme of the meeting. This is followed by an opportunity to network over food and drinks. ELRIG will host six networking events during 2020. Planned locations are Cambridge, Cheshire, London, Nottingham, Oxford and Scotland. We expect an average of 50 delegates per event, and limit the sponsorship to a maximum of 5 vendors. Events are held in academic or company facilities, to encourage local delegates to “drop in” after work. The cost of a table top for these events is £500 which includes:

• 1m x 0.5m table top exhibition space• 5 minute technology spotlight to the entire

audience• Logo on programme and web site• Participant attendee list• All refreshments included

Pharmaceutical Flow Cytometry & Imaging 2020

GlaxoSmithKline, Stevenage24 - 25 November 2020

ELRIG Networking Events 2020

Locations across the UKThroughout 2020

Examining the prospects for structural biology and biophysics in complex and more physiological systems and in supporting the entire discovery process from target identification through to assessment of target engagement

• Translational Flow Cytometry and Imaging in Drug Discovery and Development

Next generation instrumentation, and probe and sensor technology for pharmaceutical research.

• Novel and Emerging Technologies

Exploration of the latest systems approaches, utilising functional genomic technologies to link the genome and proteome to cellular regulation and function, for predictive medicine.

• Next generation Cytomics in Pharmaceutical Research

We aim to bring together the research community working in the field of flow cytometry and imaging with interests in developing and applying the technology for pharmaceutical research. Join scientists from pharma, biotech, CROs and academia to hear talks given by speakers at the cutting edge of cytometry, take part in commercial vendor lab-based workshops, network at the exhibition, innovation forum and speakers dinner and gain strategic insights into solutions for increasing the success of drug discovery and development.

January 2020:March 2020:

May 2020: June 2020: July 2020:

November 2020:

Provisional 2020 Dates

ELRIG Events 2020

#ELRIG

BioCity, ScotlandOxfordThe Francis Crick Institute, LondonBioCity, NottinghamCambridgeAlderley Park, Cheshire

Drug Discovery 2019 Sponsors

#ELRIG

Miltenyi Biotec GmbH Miltenyi Biotec provides products that advance biomedical research and cellular therapy. Our innovative tools support research from basic research to translational research to clinical application. Our 30 years of expertise includes immunology, stem cell biology, neuroscience, and cancer. Miltenyi Biotec has 2,500 employees in 28 countries. www.miltenyibiotec.com

NanoTemper Technologies Our mission at NanoTemper Technologies is to enable everyone to do science that matters by always pushing the limits. We’re focused on making biophysical tools accessible to anyone looking to characterize proteins in any industry. If you need fast, non-stop and highly sensitive affinity-based hit identification and lead validation, or want to measure binding interactions, characterize protein stability or protein quality, let’s talk. www.nanotempertech.com

Industry Insider Sponsors

LifeArc LifeArc is an independent medical research charity. We advance translation of early science into health care treatments or diagnostics that can be made available to patients. We have been doing this for more than 25 years and our work has resulted in a diagnostic for antibiotic resistance and four licensed medicines. www.lifearc.org

Metrion Biosciences Ltd Metrion Biosciences offers a range of high quality ion channel screening assays on a fee-for-service or collaborative basis. Metrion’s expertise includes in vitro cardiac ion channel safety assays such as hERG, translational native cell and phenotypic assays for neurological and cardiotoxicity testing and a range of ion channel drug discovery services. www.metrionbiosciences.com

Thought Leader Sponsor

Sygnature Discovery Sygnature Discovery is a leading drug discovery provider, offering a full range of integrated and single discipline services across biology, in vivo pharmacology, medicinal/computational chemistry, and DMPK/Tox. Since 2011, 30 compounds discovered by Sygnature Scientists have entered pre-clinical development with 14 advancing to clinical trials. www.sygnaturediscovery.com

Platinum Sponsors

Silver Sponsors

Bronze Sponsors

#ELRIG

Drug Discovery 2019 Sponsors

Eurofins Discovery www.eurofinsdiscoveryservices.com

Hamilton Sales and Service UK Ltdwww.hamiltoncompany.com

Astech Projects Ltdwww.astechprojects.co.uk

Bio-Rad Laboratories Ltdwww.bio-rad.com

BioTek Instruments Ltdwww.biotek.com

CASwww.cas.org

Cisbiowww.cisbio.com

Formulatrix, Inc.www.formulatrix.com

Genedata AGwww.genedata.com/screener

LabLogic Systems Ltdwww.lablogic.com

LGC - ATCCwww.lgcstandards-atcc.org

Merckwww.sigmaaldrich.com/

Nexcelom Bioscience Ltdwww.nexcelom.com

Pelago Bioscience ABwww.pelagobio.com

Promega UK Ltdwww.promega.com

Sphere Fluidics Ltdwww.spherefluidics.com

Thermo Fisher Scientificwww.thermoscientific.com

Gold Sponsors

Career Partners

GlaxoSmithKlinewww.gsk.com/en-gb/careers

Langton Howarthwww.langtonhowarth.co.uk

Beckman Coulter Life Sciences & Labcyte Inc.www.beckman.com / www.labcyte.com

BMG LABTECH Ltdwww.bmglabtech.com

Brooks Life Sciencewww.brookslifesciences.com

INTEGRA Bioscience Ltdwww.integra-biosciences.com

Sarstedt Ltdwww.sarstedt.com

Sartorius Stedim Biotechwww.tapbiosystems.com

Tecan UK Ltdwww.tecan.com

acCELLerate GmbHwww.accellerate.me

ChemoMetecwww.chemometec.com

Proteome Sciences Plcwww.proteomics.com

Admescope Ltdwww.admescope.com

Creoptix AGwww.creoptix.com

Reaction Biology Corporationwww.reactionbiology.com

Analytik Jena AG www.analytik-jena.com

CytoSMART Technologies B.V.www.cytosmart.com

Repositivewww./repositive.io

Andrew Alliancewww.andrewalliance.com

Dispendixwww.dispendix.com

ReproCELLwww.reprocell.com

Applied Scientific Technologies UK Ltdwww.appliedst.co.uk

Fluidic Analyticswww.fluidic.com

RxNetwww.rx-network.com

Aptamer Group Limited www.aptamergroup.co.uk

Fluidigm UK Ltdwww.fluidigm.com

STEMCELL Technologieswww.stemcell.com

Ardigenwww.ardigen.com

GC biotechwww.gcbiotech.com

Stratech Scientific Ltdwww.stratech.co.uk

Aurelia Biosciencewww.aureliabio.com

Greiner Bio Onewww.gbo.com

Synthegowww.synthego.com

BioAscent Discovery Ltdwww.bioascent.com

Hamamatsu Photonics UK Ltdwww.hamamatsu.com

Taconicwww.taconic.com

BioIVTwww.bioivt.com

HighRes Biosolutions Ltdwww.highresbio.com

Tissue Solutionswww.tissue-solutions.com

BlueCatBio GmbHwww.bluecatbio.com

I&L Biosystems UK Ltdwww.il-biosystems.com/de-en/

Titian Software Ltdwww.titian.co.uk

Cambridge Biosciencewww.bioscience.co.uk

LightOxwww.lightox.co.uk

Twist Biosciencewww.twistbioscience.com

Cambridge Research Biochemicalswww.crbdiscovery.com

Medicines Discovery Catapultwww.md.catapult.org.uk

UPM-Kymmene Corporationwww.upmbiomedicals.com

Cancer Research UKwww.cancerresearchuk.org

Mimetas B.V.www.mimetas.com

XenoGesis Ltdwww.xenogesis.com

CBRE Integrated Laboratory Solutionswww.cbre.co.uk

National Physical Laboratorywww.npl.co.uk

Zinsser Analytic GmbHwww.zinsser-analytic.com

Cell Signaling Technologywww.cellsignal.com

PAA Ltdwww.paa-automation.com

Drug Discovery 2019 Media Partners

Drug Discovery 2019 Exhibitors

Drug Discovery 2019 Innovation ZoneAtelerix Ltdwww.atelerix.co.uk

Cellbox Solutionswww.cellbox-solutions.com

Manchester BIOGELwww.manchesterbiogel.com

BioMedha Limitedwww.biomedha.com

Cytomos Limitedwww.cytomos.com

Microlight3Dwww.microlight3d.com

British Society for Nanomedicinewww.britishsocietynanomedicine.org

Enzymlogicwww.enzymlogic.com

ScreenIn3Dwww.screenin3d.com

Cell & Softwww.linksium.fr/projet/mecachips

Imrali Inventionswww.imraliinvention.com

Stream Bio Ltdwww.streambio.co.uk

Cell Guidance Systemswww.cellgs.com

innoVitro GmbHwww.innovitro.de

Alderley Park Acceleratorwww.alderleypark.co.uk/accelerator

Drug Discovery Todaywww.drugdiscoverytoday.com

SelectSciencewww.selectscience.net

BioCitywww.biocity.co.uk/

Drug Discovery Worldwww.ddw-online.com

Technology Networkswww.technologynetworks.com

Biostratawww.biostratamarketing.com

Drug Target Reviewwww.drugtargetreview.com

UKSPAwww.scienceparks.co.uk

British Pharmacological Societywww.bps.ac.uk

European Biopharmaceutical Reviewwww.samedanltd.com/magazine/12

UK Pharmacogenetics & Stratified Medicine Networkwww.uk-pgx-stratmed.co.uk

Drug Discovery Newswww.ddn-news.com

GENwww.genengnews.com

Zyme Communicationswww.zymecommunications.com

#ELRIG

annual elrig drug discovery event. our organising committee and session chairs have been working...

Documents